H.C. Wainwright initiated coverage of Ardelyx with a Buy rating and $9 price target. The analyst says the company is disrupting two therapeutic markets with a “unique and highly differentiated” mechanism of action. The firm says tenapanor for the treatment of adults with irritable bowel syndrome with constipation is meeting or exceeding guidance and continues to gain momentum and take market share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ARDX:
- Biotech Alert: Searches spiking for these stocks today
- Ardelyx (NASDAQ:ARDX) Jumps With Likely New Drug Approval
- Netflix upgraded, Olaplex downgraded: Wall Street’s top analyst calls
- Ardelyx upgraded to Overweight from Neutral at Cantor Fitzgerald
- Ardelyx price target raised to $8.50 from $7.50 at Ladenburg